171 related articles for article (PubMed ID: 30201241)
1. The Tradeoff of Cancer Drug Regulatory Policy: Faster Approvals for One Means Less Knowledge for Another.
Tao D; Schott S; Prasad V
Am J Med; 2019 Mar; 132(3):e509-e511. PubMed ID: 30201241
[No Abstract] [Full Text] [Related]
2. Cancer drug approval in the United States, Europe, and Japan.
Milsted RA
Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
[No Abstract] [Full Text] [Related]
3. Food and Drug Administration responds to pressure for expanded drug access.
Brower V
J Natl Cancer Inst; 2014 Jun; 106(6):dju171. PubMed ID: 24907387
[No Abstract] [Full Text] [Related]
4. Inappropriate use of progression-free survival in cancer drug approvals.
Naci H; Davis C
BMJ; 2020 Mar; 368():m770. PubMed ID: 32156802
[No Abstract] [Full Text] [Related]
5. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
[TBL] [Abstract][Full Text] [Related]
6. New Indications and Approvals for Anticancer Drugs.
Aschenbrenner DS
Am J Nurs; 2021 Dec; 121(12):16-17. PubMed ID: 34792500
[TBL] [Abstract][Full Text] [Related]
7. Expanded Access Allows for Compassionate Use of Investigational Cancer Drugs.
Miller D
ONS Connect; 2015 Jun; 30(2):47. PubMed ID: 26137830
[No Abstract] [Full Text] [Related]
8. 2011 FDA drug approvals.
Mullard A
Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
[No Abstract] [Full Text] [Related]
9. Oncology approvals in 2020: a year of firsts in the midst of a pandemic.
Amiri-Kordestani L; Pazdur R
Nat Rev Clin Oncol; 2021 Mar; 18(3):129-130. PubMed ID: 33514911
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant trials could speed up drug approvals.
Peres J
J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
[No Abstract] [Full Text] [Related]
11. Are european cancer patients getting a fair deal?
McVie JG
Ann Oncol; 2001 Aug; 12(8):1033-5. PubMed ID: 11583176
[No Abstract] [Full Text] [Related]
12. Oncology drugs enter the US market faster than in Europe but cost more.
Mitka M
JAMA; 2012 Aug; 308(6):555. PubMed ID: 22871850
[No Abstract] [Full Text] [Related]
13. Rare cancer trial design: lessons from FDA approvals.
Gaddipati H; Liu K; Pariser A; Pazdur R
Clin Cancer Res; 2012 Oct; 18(19):5172-8. PubMed ID: 22718862
[TBL] [Abstract][Full Text] [Related]
14. New drug approvals in oncology.
Kurzrock R; Kantarjian HM; Kesselheim AS; Sigal EV
Nat Rev Clin Oncol; 2020 Mar; 17(3):140-146. PubMed ID: 32020042
[TBL] [Abstract][Full Text] [Related]
15. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
Roberts SA; Allen JD; Sigal EV
Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577
[TBL] [Abstract][Full Text] [Related]
16. The Ethical Challenges of Compassionate Use.
Caplan AL; Ray A
JAMA; 2016 Mar; 315(10):979-80. PubMed ID: 26868205
[No Abstract] [Full Text] [Related]
17. Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada.
Kluetz PG; O'Connor DJ; Soltys K
Lancet Oncol; 2018 May; 19(5):e267-e274. PubMed ID: 29726391
[TBL] [Abstract][Full Text] [Related]
18. Single-arm trials for US Food and Drug Administration cancer drug approvals: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.: Although there are some challenges in using single-arm studies for accelerated drug approvals, it can make a difference in getting drugs previously approved for other uses to patients.
Nierengarten MB
Cancer; 2023 Jun; 129(11):1626. PubMed ID: 37158643
[No Abstract] [Full Text] [Related]
19. Hiding behind agency discretion: the Food and Drug Administration's personal use drug importation policy.
Reichertz PS; Friend MS
Cornell J Law Public Policy; 2000; 9():493-521. PubMed ID: 11067734
[No Abstract] [Full Text] [Related]
20. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
Khozin S; Liu K; Jarow JP; Pazdur R
Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
[No Abstract] [Full Text] [Related]
[Next] [New Search]